Biotechnology company Entera Health reported on Thursday the receipt of the IRB approval to commence a clinical trial in Barcelona Spain using EnteraGam to manage the symptoms associated with COVID-19 infections in partnership with Lemus Buhils.
The companies said EnteraGam (a serum-derived bovine immunoglobulin/protein isolate, SBI) is a medical food product intended for the dietary management of chronic diarrhea and loose stools. It is administered under medical supervision in the USA.
Titled "Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People with COVID-19 (Spanish PICNIC Study)" , the trial will investigate the use of EnteraGam to manage inflammation and symptom severity in patients with mild-to-moderate SARS-CoV-2 infections.
This randomized open-label Spanish PICNIC clinical trial aims to enroll 420 subjects with SARS-CoV-2 infection with mild-to-moderate symptom severity, including respiratory distress, coughing and shortness of breath. The primary endpoints of the trial are the change in plasma IL-6 levels between entry and the percentage of patients with disease progression by Week two, concluded the partnership.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007